The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth

Clinical Cancer Research

Volumn 6, Issue 8, 2000, Pages 3319-3326

  Krystal, Geoffrey W ^a,b,d   Honsawek, Sittisak ^b   Litz, Julie ^a   Buchdunger, Elisabeth ^c  

^a Division of Hematology/Oncology   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; DNA FRAGMENT; ETOPOSIDE; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SOMATOMEDIN C; STEM CELL FACTOR;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LUNG SMALL CELL CANCER; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CARBOPLATIN; CARCINOMA, SMALL CELL; CELL DIVISION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ENZYME ACTIVATION; ENZYME INHIBITORS; GROWTH INHIBITORS; HUMANS; LUNG NEOPLASMS; MITOGEN-ACTIVATED PROTEIN KINASES; PIPERAZINES; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; STEM CELL FACTOR; TUMOR CELLS, CULTURED;

EID: 0033883653     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Hunter, T. Oncoprotein networks. Cell, 88: 333-346, 1997.
2. Marshall, C. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell, 80: 179-185, 1995.
3. Gibbs. J., and Oliff, A. Pharmaceutical research in molecular oncology. Cell, 79: 193-198, 1994.
4. Levitski, A., and Gazit, A. Tyrosine kinase inhibition; an approach to drug development. Science (Washington DC), 267: 1782-1788, 1995.
5. Mendelsohn, J. Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clin. Cancer Res., 3: 2703-2707, 1997.
6. Fry, D. W., Kraker, A. J., McMichael, A., Ambroso, L. A., Nelson, J. M., Leopold, W. R., Conners, R. W., and Bridges, A. J. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science (Washington DC), 269: 1093-1095, 1994.
7. Buchdunger, E., Mett, H., Trinks, U., Regenass, U., Muller, M., Meyer, T., Beilstein, P., Wirz, B., Schneider, P., Traxler, P., and Lydon, N. 4,5-bis(4-fluoroanilino)phthalimide: a selective inhibitor of the epidermal growth factor receptor signal transduction pathway with potent in vivo antitumor activity. Clin. Cancer Res., 1: 813-821, 1995.
8. Strawn, L. M., McMahon, G., App, H., Schreck, R., Kuchler, W. R., Longhi, M. P., Hui, T. H., Tang, C., Levitzki, A., Gazit, A., Chen, I., Ken, G., Orfi, L., Risau, W., Flamme, I., Ullrich, A., Hirth, K. P., and Shawver, L. K. FIk-1 as a target for tumor growth inhibition. Cancer Res., 56: 3540-3545, 1996.
9. Buchdunger, E., Zimmermann, J., Mett, H., Meyer, T., Muller, M., Druker, B. J., and Lydon N. B. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res., 56: 100-104, 1996.
10. Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., and Lydon, N. B. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med., 2: 561-566, 1996.
11. Faderl, S., Talpaz, M., Estrov, Z., O'Brien, S., Kurzrock, R., and Kantarjian, H. M. The biology of chronic myeloid leukemia. N. Engl. J. Med., 341: 164-72, 1999.
12. Carroll, M., Ohno-Jones, S., Tamura, S., Buchdunger, E., Zimmermann, J., Lydon, N. B., Gilliland, D. G., and Druker, B. J. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood, 90: 4947-4952, 1997.
13. Deininger, M. W., Goldman, J. M., Lydon N., and Melo, J. V. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood, 90: 3691-3698, 1997.
14. Beran, M., Cao, X., Estrov, Z., Jeha, S., Jin, G., O'Brien, S., Talpaz, M., Arlinghaus, R. B., Lydon, N. B., and Kantarjian, H. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148). Clin. Cancer Res., 4: 1661-1672, 1998.
15. le Coutre, P., Mologni, L., Cleris, L., Marchesi, E., Buchdunger, E., Giardini, R., Formelli, F., and Gambacorti-Passerini. C. In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor. J. Natl. Cancer Inst., 91: 163-8, 1999.
16. Sauseville, E. A. A Bcr/Abl antagonist for chronic myelogenous leukemia: a promising path for progress emerges. J. Natl. Cancer Inst., 91: 102-103, 1999.
17. Yarden, Y., Kuang, W. J., Yang-Feng, T., Coussens, L., Munemitsu, S., Dull, T. J., Chen, E., Schlessinger, J., Francke, U., and Ullrich, A. Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J., 6: 3341-3351, 1987.
18. Lev, S., Blechman, J. M., Givol, D., and Yarden, Y. Steel factor and c-kit proto-oncogene: genetic lessons in signal transduction. Crit. Rev. Oncog., 5: 141-168, 1994.
19. Hibi, K., Takahashi, T., Sekido, Y., Ueda, R., Hida, T., Ariyoshi, Y., Takagi, H., and Takahashi, T. Coexpression of the stem cell factor and the c-kit genes in small-cell lung cancer. Oncogene, 6: 2291-2296, 1991.
20. Plummer III, H., Catlett, J., Leftwich, J., Armstrong, B., Carlson, P., Huff, T., and Krystal, G. c-myc expression correlates with suppression of c-kit proto-oncogene expression in small cell lung cancer cell lines. Cancer Res., 53: 4337-4342, 1993.
21. Rygaard, K., Nakamura, T., and Spang-Thomsen, M. Expression of the proto-oncogenes c-met and c-kit and their ligands, hepatocyte growth factor/scatter factor and stem cell factor in SCLC cell lines and xenografts. Br. J. Cancer, 67: 37-46, 1993.
22. Sekido, Y., Takahashi, T., Ueda, R., Takahashi, M., Suzuki, H., Nishida, K., Tsukamoto, T., Hida, T., Shimokata, K., Zsebo, K. M., and Takahashi, T. Recombinant human stem cell factor mediates chemotaxis of small-cell lung cancer cell lines aberrantly expressing the c-kit proto-oncogene. Cancer Res., 53: 1709-1714, 1993.
23. Krystal, G. W., Carlson, P., and Litz, J. Induction of apoptosis and inhibition of small cell lung cancer growth by the quinoxaline tyrphostins. Cancer Res., 57: 2203-2208, 1997.
24. Krystal, G. W., Hines, S., and Organ, C. Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor. Cancer Res., 56: 370-376, 1996.
25. Carney, D. N., Gazdar, A. F., Bepler, G., Guccion, J. G., Marangos, P. J., Moody, T. W., Zweig, M. H., and Minna, J. D. Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer Res., 45: 2913-2923, 1985.
26. Carmichael J., DeGraf, W. G., Gazdar, A. D., Minna, J. D., and Mitchell, J. B. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res., 47: 936-942, 1987.
27. Gavrieli, Y., Sherman, Y., and Ben-Sassoon, S. A. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragments. J. Cell Biol., 119: 493-501, 1992.
28. Hancock, M. C., Langton, B. C., Chan, T., Toy, P., Monahan, J. J., Mischak, R. P., and Shawver, L. K. A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines. Cancer Res., 51: 4575-4580, 1991.
29. Fan, Z., Baselga, J., Masui, H., and Mendelsohn, J. Anti-tumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res., 53: 4322-4328, 1993.
30. HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J. Clin. Oncol., 16: 2659-2671, 1998.
31. Ihde, D., Pass, H., and Glatstein, E. Small cell lung cancer. In: V. DeVita, S. Hellman, and S. Rosenberg (eds.), Cancer: Principles & Practice of Oncology, pp. 911-949. Philadelphia: Lippincott, 1997.
32. Aisner, J. Extensive-disease small-cell lung cancer: the thrill of victory: the agony of defeat. J. Clin. Oncol., 14: 658-665, 1996.
33. Drucker, B. J., Sawyer, C. L., Tolpaz, M., Resta, D., Ping, B., and Ford, J. Phase I trial of a specific ABL tyrosine kinase inhibitor, CGP 57148, in interferon refractory chronic myelogenous leukemia patients. Blood, 92 (Suppl. 1): 1034a, 1998.
34. Kovalenko, M., Gazit, A., Bohmer, A., Rorsman, C., Ronnstrand, L., Heldin, C-H., Waltenberger, J., Bohmer, F., and Levitski, A. Selective platelet-derived growth factor receptor kinase blockers reverse cis-transformation. Cancer Res., 54: 6106-6114, 1994.
35. Ihde, D. C., Mulshine, J. L., Kramer, B. S., Steinberg, S. M., Linnoila, R. I., Gazdar, A. F., Edison, M., Phelps, R. M., Lesar, M., Phares, J. C., Grayson, J., Minna, J. D., and Johnson, B. E. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. J. Clin. Oncol., 12: 2022-2034, 1994.
36. Tsai, C. M., Levitzki, A., Wu, L. H., Chang, K. T., Cheng, C. C., Gazit, A., and Perng, R. P. Enhancement of chemosensitivity by tyrphostin AG 825 in high-p185(neu) expressing non-small cell lung cancer cells. Cancer Res., 56: 1068-1074, 1996.